Yori Yuliandra, PhD

Associate Professor at the Faculty of Pharmacy, Andalas University, Indonesia. I also serve as the Head of Library at Andalas University and as Managing Editor for the Journal of Clinical and Pharmaceutical Sciences.

My research focuses on addressing global health challenges through drug discovery and development, as well as on understanding drug action at a fundamental level through molecular pharmacology and molecular modeling. A primary focus of my work is discovering and optimizing treatments for antimicrobial resistance.

🎓 Educational Background

PhD in Pharmacy (PhD), The University of Sydney, Australia (2023), under Australia Awards Scholarship
Master of Pharmacy (M.Farm), Andalas University, Indonesia (2012)
Bachelor of Pharmacy (S.Farm), Andalas University, Indonesia (2007)

💼 Professional and Leadership Experiences

Associate Professor, Faculty of Pharmacy, Andalas University (2020-current)
Head of Library, Universitas Andalas, Padang, Indonesia (2024–current).
Managing Editor, Journal of Clinical and Pharmaceutical Sciences (Co-founder & Editor since 2014, ).

📖 Recent Publications

Improved Solubility and Dissolution of Etoricoxib via Multicomponent Crystallization with Meglumine

Read full article

A novel cocrystal approach celecoxib with piperine: Simultaneously enhance dissolution rate and compressibility

Read full article

Integrating Computational Methods into Antibacterial Drug Discovery and Development from Natural Products

Read full article

The role of adjuvants in overcoming antibacterial resistance due to enzymatic drug modification

Read full article

Viel All Publications -->

🔬 Active Research Grants

Potential of Kalincuang of Gambier as a Neuroprotective Agent in Chronic Cerebral Hypoperfusion (CCH) Rat Models: In Silico and In Vivo Pharmacological Approaches to Cognitive Enhancement and Nanoemulsion Formulation

Funding Agency / Scheme: Research and Innovation Initiative for New Indonesia (RIIM Kompetisi) – BRIN 2026
Role: Principal Investigator
Key Focus: Computational pharmacology, neuroprotection, cognitive impairment, natural product nanoemulsion

Targeting Inflammatory Cytokines and Oxidative Stress Pathways for Osteoarthritis Management Using Bioactive Compounds from Pometia pinnata and Lansium domesticum

Funding Agency / Scheme: Indonesian Collaborative Research (Riset Kolaborasi Indonesia - RKI) 2026
Role: Principal Investigator (Co-host)
Key Focus: Bioactive phytochemicals, anti-inflammatory mechanisms, molecular modeling, osteoarthritis therapeutics.

Viel all research grants >>

FEATURED FROM THE JOURNAL ARTICLE

The role of adjuvants in overcoming antibacterial resistance due to enzymatic drug modification

Antibacterial resistance is a prominent issue with monotherapy often leading to treatment failure in serious infections. Many mechanisms can lead to antibacterial resistance including deactivation of antibacterial agents by bacterial enzymes. Enzymatic drug modification confers resistance to β-lactams, aminoglycosides, chloramphenicol, macrolides, isoniazid, rifamycins, fosfomycin and lincosamides. Novel enzyme inhibitor adjuvants have been developed in an attempt to overcome resistance to these agents, only a few of which have so far reached the market. This review discusses the different enzymatic processes that lead to deactivation of antibacterial agents and provides an update on the current and potential enzyme inhibitors that may restore bacterial susceptibility.